Literature DB >> 17327887

Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study.

Neeltje E M van Haren1, Hilleke E Hulshoff Pol, Hugo G Schnack, Wiepke Cahn, René C W Mandl, D Louis Collins, Alan C Evans, René S Kahn.   

Abstract

Recent volumetric magnetic resonance imaging (MRI) studies have suggested brain volume changes in schizophrenia to be progressive in nature. Whether this is a global process or some brain areas are more affected than others is not known. In a 5-year longitudinal study, MRI whole brain scans were obtained from 96 patients with schizophrenia and 113 matched healthy comparison subjects. Changes over time in focal gray and white matter were measured with voxel-based morphometry throughout the brain. Over the 5-year interval, excessive decreases in gray matter density were found in patients in the left superior frontal area (Brodmann areas 9/10), left superior temporal gyrus (Brodmann area 42), right caudate nucleus, and right thalamus as compared to healthy individuals. Excessive gray matter density decrease in the superior frontal gray matter was related to increased number of hospitalizations, whereas a higher cumulative dose of clozapine and olanzapine during the scan interval was related to lesser decreases in this area. In conclusion, gray matter density loss occurs across the course of the illness in schizophrenia, predominantly in left frontal and temporal cortices. Moreover, the progression in left frontal density loss appears to be related to an increased number of psychotic episodes, with atypical antipsychotic medication attenuating these changes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327887     DOI: 10.1038/sj.npp.1301347

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  98 in total

1.  The field of schizophrenia: strengths, weaknesses, opportunities, and threats.

Authors:  John M Kane; Barbara Cornblatt; Christoph U Correll; Terry Goldberg; Todd Lencz; Anil K Malhotra; Delbert Robinson; Philip Szeszko
Journal:  Schizophr Bull       Date:  2011-11-18       Impact factor: 9.306

2.  Re: Progressive volume reduction and its relation to the different stages of schizophrenia.

Authors:  Takeshi Yoshida; Robert W McCarley; Margaret A Niznikiewicz
Journal:  Schizophr Res       Date:  2010-06-15       Impact factor: 4.939

3.  Longitudinal progression of frontal and temporal lobe changes in schizophrenia.

Authors:  Derin J Cobia; Matthew J Smith; Lei Wang; John G Csernansky
Journal:  Schizophr Res       Date:  2012-05-29       Impact factor: 4.939

4.  Relative risk of probabilistic category learning deficits in patients with schizophrenia and their siblings.

Authors:  Thomas W Weickert; Terry E Goldberg; Michael F Egan; Jose A Apud; Martijn Meeter; Catherine E Myers; Mark A Gluck; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2010-02-20       Impact factor: 13.382

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

6.  Neural correlates of probabilistic category learning in patients with schizophrenia.

Authors:  Thomas W Weickert; Terry E Goldberg; Joseph H Callicott; Qiang Chen; Jose A Apud; Sumitra Das; Brad J Zoltick; Michael F Egan; Martijn Meeter; Catherine Myers; Mark A Gluck; Daniel R Weinberger; Venkata S Mattay
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

7.  Identification of targeted analyte clusters for studies of schizophrenia.

Authors:  Tammy M K Cheng; Yu-En Lu; Paul C Guest; Hassan Rahmoune; Laura W Harris; Lan Wang; Dan Ma; Victoria Stelzhammer; Yagnesh Umrania; Matt T Wayland; Pietro Lió; Sabine Bahn
Journal:  Mol Cell Proteomics       Date:  2009-12-10       Impact factor: 5.911

8.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

9.  Progressive deformation of deep brain nuclei and hippocampal-amygdala formation in schizophrenia.

Authors:  Lei Wang; Daniel Mamah; Michael P Harms; Meghana Karnik; Joseph L Price; Mokhtar H Gado; Paul A Thompson; Deanna M Barch; Michael I Miller; John G Csernansky
Journal:  Biol Psychiatry       Date:  2008-09-23       Impact factor: 13.382

Review 10.  Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models.

Authors:  Hanna Jaaro-Peled; Yavuz Ayhan; Mikhail V Pletnikov; Akira Sawa
Journal:  Schizophr Bull       Date:  2009-11-10       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.